This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.09.046v1 49/6/631    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berry, C. Articles by Bourassa, M. G. Search for Related Content PubMed Articles by Berry, C. Articles by Bourassa, M. G.

STATE-OF-THE-ART PAPERS

Coronary Heart Disease in Patients With Diabetes

Part I: Recent Advances in Prevention and Noninvasive Management

Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada

Manuscript received July 11, 2006; revised manuscript received September 7, 2006, accepted September 11, 2006.

^_* Reprint requests and correspondence: Dr. Martial G. Bourassa, Research Center, Montreal Heart Institute, Montreal, Quebec H1T 1C8, Canada. (Email: martial.bourassa{at}icm-mhi.org).

Diabetes mellitus (DM) is a worldwide epidemic. Its prevalence is rapidly increasing in both developing and developed countries. Coronary heart disease (CHD) is highly prevalent and is the major cause of morbidity and mortality in diabetic patients. The purpose of this review is to assess the clinical impact of recent advances in the epidemiology, prevention, and management of CHD in diabetic patients. A systematic review of publications in this area, referenced in MEDLINE in the past 5 years (2000 to 2005), was undertaken. Patients with CHD and prediabetic states should undergo lifestyle modifications aimed at preventing DM. Pharmacological prevention of DM is also promising but requires further study. In patients with CHD and DM, routine use of aspirin and an angiotensin-converting enzyme inhibitor (ACE-I)—unless contraindicated or not tolerated—and strict glycemic, blood pressure, and lipid control are strongly recommended. The targets for secondary prevention in these patients are relatively well defined, but the strategies to achieve them vary and must be individualized. Intense insulin therapy might be needed for glycemic control, and high-dose statin therapy might be needed for lipid control. For blood pressure control, ACE-Is and angiotensin receptor blockers are considered as first-line therapy. Noncompliance, particularly with lifestyle measures, and underprescription of evidence-based therapies remain important unsolved problems.

Abbreviations and Acronyms   ACE-I = angiotensin-converting enzyme inhibitor   ARB = angiotensin receptor blocker   CHD = coronary heart disease   CVD = cardiovascular disease   HbA1c = hemoglobin A1c   HDL-C = high-density lipoprotein cholesterol   IFG = impaired fasting glucose   IGT = impaired glucose tolerance   LDL-C = low-density lipoprotein cholesterol   NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III   OGTT = oral glucose tolerance test

This article has been cited by other articles:

				B. Marcheix, F. Vanden Eynden, P. Demers, D. Bouchard, and R. Cartier Influence of diabetes mellitus on long-term survival in systematic off-pump coronary artery bypass surgery. Ann. Thorac. Surg., October 1, 2008; 86(4): 1181 - 1188. [Abstract] [Full Text] [PDF]

				W. Acampa, M. Petretta, L. Evangelista, G. Nappi, L. Luongo, M. P. Petretta, and A. Cuocolo Stress cardiac single-photon emission computed tomographic imaging late after coronary artery bypass surgery for risk stratification and estimation of time to cardiac events J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 46 - 51. [Abstract] [Full Text] [PDF]

				A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF]

				T. Kanda, S. Wakino, K. Hayashi, and J. Plutzky Cardiovascular Disease, Chronic Kidney Disease, and Type 2 Diabetes Mellitus: Proceeding with Caution at a Dangerous Intersection J. Am. Soc. Nephrol., January 1, 2008; 19(1): 4 - 7. [Full Text] [PDF]

				Management of Stable Coronary Disease N. Engl. J. Med., October 25, 2007; 357(17): 1762 - 1766. [Full Text] [PDF]

				L. Cortigiani, F. Rigo, S. Gherardi, R. Sicari, M. Galderisi, F. Bovenzi, and E. Picano Additional Prognostic Value of Coronary Flow Reserve in Diabetic and Nondiabetic Patients With Negative Dipyridamole Stress Echocardiography by Wall Motion Criteria J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1354 - 1361. [Abstract] [Full Text] [PDF]

				L. Terre Behavioral Medicine Review: Strategic Management of Diabetes Risk American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 351 - 355. [Abstract] [PDF]